Released Jun 14, 2019, after the close
10-Q filed Jun 14, 2019, 45 days after period end · 0001654954-19-007348
Q2 2019 · 10-Q
Revenue$5.15M$5.15M +36.8% vs Q2 2018+12.8% vs Q1 2019
Net Income$707.48K$707.48K N/M vs Q2 2018+50.2% vs Q1 2019
EPS, diluted—
Gross Profit$1,593,402+53.7%
Operating Income$476,928N/M
Operating Cash Flow-$822,917N/M
Free Cash Flowderived-$858,678N/M
Margins · derived
Gross margin30.9%+3.4 pt vs Q2 2018
Operating margin9.3%+9.5 pt vs Q2 2018
Net margin13.7%+17.1 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $5.15M | $3.77M | $3.92M | — |
| Net Income | $707.48K | -$128.35K | -$322.76K | $37.20K |
| EPS Diluted | — | -$0.01 | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR